BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Carlo Messina, Carlo Cattrini, Davide Soldato, Giacomo Vallome, Orazio Caffo, Elena Castro, David Olmos, Francesco Boccardo, Elisa Zanardi

Research output: Contribution to journalReview articlepeer-review


Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and with poor outcomes in patients with mCRPC. In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. However, concerns still remain on the role of extensive mutational testing in prostate cancer patients, given the implications for patients and for their progeny. The present comprehensive review attempts to provide an overview of BRCA mutations in prostate cancer, focusing on their prognostic and predictive roles.

Original languageEnglish
Article number4986365
JournalJournal of Oncology
Publication statusPublished - 2020

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications'. Together they form a unique fingerprint.

Cite this